medigraphic.com

2019, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2019; 57 (3)

Burkitt's lymphoma nodular cystic hapatosplenic, in HIV patient. Case report

De la Cruz-Hernández I, Mejía-Martínez JC, Soberanes-Cerino CJ, Mejía-Picasso CA

Language: Spanish
References: 20
Page: 187-190
PDF size: 680.37 Kb.


ABSTRACT

Background: Patients with human immunodeficiency virus (HIV) are more likely to develop cancer. Malignant lymphomas are the main cancer group seen in these patients. Diffuse large B-cell lymphoma including central nervous system lymphoma and Burkitt's lymphoma account for 90% of HIV-related non-Hodgkin's lymphomas.
Clinical case: A 22-year-old man with fever up to 39 ° C, malaise, excessive tiredness and night sweats, loss of 8 kg of weight, abdominal pain in the right hypochondrium, all 5 months before hospitalization. Hemoglobin: 9.5 g/dL, leukocytes 5.13 x 103/mm3, platelets 124 000 cel/mm3; albumin 2.9 g/dL, alanine aminotransferase 28 IU/L, aspartate aminotransferase 105 IU/L; HIV reactive, beta 2 microglobulin: 20 000 ng/mL. Viral load for HIV 100 034 cp/mL, CD4: 76 cel/mcL (5%). It was performed abdominal ultrasound and denoted cysts in the liver and spleen. Abdominal-pelvic computed tomography with hepatosplenomegaly, retroperitoneal and inguinal adenopathies and free fluid in abdominal cavity. Splenectomy was performed and Burkitt's lymphoma was reported in the histopathological study.
Conclusion: HIV predisposes patients to any type of cáncer. Intra-abdominal findings should be a warning of lymphoma suspicious and may occur from infiltration of the small intestine, solid organ and soft tissues.


REFERENCES

  1. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28(4):453-65. DOI: 10.1097/QAD.0000000000000071

  2. Linke-Serinsöz E, Fend F, Quintanilla-Martinez L. Human immunodeficiency virus (HIV) and Epstein-Barr Virus (EBV) related lymphomas, pathology view point. Semin Diagn Pathol. 2017;34(4):352-63. DOI: 10.1053/j.semdp.2017.04.003

  3. Dolcetti R, Gloghini A, Caruso A, Carbone A. A lymphomagenic role for HIV beyond immune suppression? Blood. 2016;127(11):1403-9. DOI: 10.1182/blood-2015-11- 681411

  4. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757-68.

  5. Johnson KA, Tung K, Mead G, Sweetenham J. The imaging of Burkitt’s and Burkitt-like lymphoma. Clin Rad. 1998;53 (11):835-41. DOI: 10.1016/s0009-9260(98)80196-7

  6. Balthazar EJ, Noordhoorn M, Megibow AJ, Gordon RB. CT of small-bowel lymphoma in immunocompetent patients and patients with AIDS: comparison of findings .AJR Am J Roentgenol. 1997;168(3):675-80. DOI: 10.2214/ajr.168.3. 9057513

  7. Spina M, Tirelli U, Zagonel V, Gloghini A, Volpe R, Babare R, et al. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection. A single institution clinicopathologic study of 75 patients. Cancer. 1998;82(4):766-74.

  8. Davi F, Delecluse HJ, Guiet P, Gabarre J, Fayon A, Gentilhomme O, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus associated non-Hodgkin's lymphomas. J Clin Oncol. 1998;16(12):3788-95.

  9. Dunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma. Hematol Oncol Clin North Am. 2016;30(6): 1333-43. DOI: 10.1016/j.hoc.2016.07.009

  10. Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: spectrum of disease. Radiographics. 1991;11(4):647-69. DOI: 10.1148/radiographics.11.4.1887120

  11. Harris AC, MacLean KA, Grunau GL, Chang SD, Martin N. Imaging Intra-abdominal Burkitt’s Lymphoma: From Discrete Bowel Wall Thickening to Diffuse Soft Tissue Infiltration. Cann Assoc Radiol J. 2017;68(3):286-92. DOI: 10.1016/j.carj.2016.08.007

  12. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev 2 Cancer. 2016;16(12):789-802. DOI: 10.1038/nrc.2016.92

  13. Carbone A, Gloghini A, Gaidano G, Cilia AM, Bassi P, Polito P, et al. Aids-related Burkitt’s-lymphoma. Morphologic and immunophenotypic study of biopsy specimens. Am J Clin Pathol. 1995;103(5):561-7. DOI: 10.1093/ajcp/103.5.561

  14. Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121(24): 4861-6. DOI: 10.1182/blood-2012-12-475558

  15. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119(20):3672-9. DOI: 10.1002/cncr.28264

  16. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104(10):3009‐20. DOI: 10.1182/blood- 2004-02-0405

  17. Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, et al. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virusinfected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. Leuk Lymphoma. 2014;55(10):2341‐8.

  18. Cortes J, Thomas D, Rios A, Koller C, O´Brien S, Jeha S, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492‐9. DOI: 10.1002/cncr.10365

  19. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virusassociated Burkitt lymphoma. Cancer. 2003;98(6):1196‐ 205. DOI: 10.1002/cncr.11628

  20. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859‐64. DOI: 10.1093/annonc/mdq677




2020     |     www.medigraphic.com